Veradermics (MANE) Equity Average (2025 - 2026)
Veradermics (MANE) reported Equity Average of $134.8 million for Q1 2026, up 347.03% on a YoY basis from $30.2 million in Q1 2025, and up 248.41% quarter-over-quarter from -$90.8 million in Q4 2025.
Veradermics (MANE) Equity Average (2025 - 2026) Analysis & Trends
Veradermics has reported Equity Average for 2 years, with the latest figure at $134.8 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 347.03% year-over-year to $134.8 million; the trailing twelve-month figure through Mar 2026 stood at $134.8 million (up 347.03% YoY), and the FY2025 full-year result was -$84.7 million, changed N/A from the prior year.
- Equity Average for Q1 2026 stood at $134.8 million, up from -$90.8 million in the prior quarter.
- The five-year high for Equity Average was $134.8 million in Q1 2026, with the low at -$90.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Veradermics | 2.13 Bn | 2.13 Bn | - | 134.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.81 Mn |
| Dec 31, 2025 | -90.84 Mn |
| Mar 31, 2025 | -54.57 Mn |